As Biotechnology companies, Allogene Therapeutics Inc. (NASDAQ:ALLO) and Infinity Pharmaceuticals Inc. (NASDAQ:INFI) are our subject to contrast. And more specifically their risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation.
Earnings and Valuation
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Allogene Therapeutics Inc. | N/A | 0.00 | 211.50M | 0.00 | 0.00 |
Infinity Pharmaceuticals Inc. | 22.15M | 4.81 | 11.25M | 1.25 | 1.28 |
In table 1 we can see Allogene Therapeutics Inc. and Infinity Pharmaceuticals Inc.’s gross revenue, earnings per share (EPS) and valuation.
Profitability
Table 2 represents Allogene Therapeutics Inc. (NASDAQ:ALLO) and Infinity Pharmaceuticals Inc. (NASDAQ:INFI)?s return on assets, net margins and return on equity.
Net Margins | Return on Equity | Return on Assets | |
Allogene Therapeutics Inc. | 0.00% | 0% | 0% |
Infinity Pharmaceuticals Inc. | -50.79% | -20.8% | -18.2% |
Liquidity
The current Quick Ratio of Allogene Therapeutics Inc. is 1.6 while its Current Ratio is 1.6. Meanwhile, Infinity Pharmaceuticals Inc. has a Current Ratio of 10.7 while its Quick Ratio is 10.7. Infinity Pharmaceuticals Inc. is better positioned to pay off its short-term and long-term debts than Allogene Therapeutics Inc.
Analyst Recommendations
The table given features the ratings and recommendations for Allogene Therapeutics Inc. and Infinity Pharmaceuticals Inc.
Sell Ratings | Hold Ratings | Buy Ratings | Rating Score | |
Allogene Therapeutics Inc. | 0 | 0 | 1 | 3.00 |
Infinity Pharmaceuticals Inc. | 1 | 1 | 1 | 2.33 |
The upside potential is 55.95% for Allogene Therapeutics Inc. with average target price of $40. Infinity Pharmaceuticals Inc. on the other hand boasts of a $3 average target price and a 60.43% potential upside. The data from earlier shows that analysts opinion suggest that Infinity Pharmaceuticals Inc. seems more appealing than Allogene Therapeutics Inc.
Institutional & Insider Ownership
Roughly 52.3% of Allogene Therapeutics Inc. shares are held by institutional investors while 54.9% of Infinity Pharmaceuticals Inc. are owned by institutional investors. Insiders held roughly 21.2% of Allogene Therapeutics Inc.’s shares. Comparatively, insiders own roughly 1.1% of Infinity Pharmaceuticals Inc.?s shares.
Performance
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
Performance (W) | Performance (M) | Performance (Q) | Performance (HY) | Performance (Y) | Performance (YTD) | |
Allogene Therapeutics Inc. | 0.66% | 5.31% | 4.72% | 0% | 0% | 18.6% |
Infinity Pharmaceuticals Inc. | -3.03% | 32.23% | 16.79% | -21.57% | -16.67% | 35.59% |
For the past year Allogene Therapeutics Inc. has weaker performance than Infinity Pharmaceuticals Inc.
Summary
Infinity Pharmaceuticals Inc. beats Allogene Therapeutics Inc. on 8 of the 12 factors.
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the research, development, and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, a CAR T cell product candidate targeting CD19, which is in clinical trials in patients with R/R B-cell precursor acute lymphoblastic leukemia; ALLO-501, an allogeneic anti-CD19 CAR T cell product candidate for the treatment of patients with R/R non-Hodgkin lymphoma; ALLO-715, an allogeneic CAR T cell product candidate for the treatment of patients with R/R multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepleting agent. It is also developing ALLO-819, an anti-Flt3 product candidate for the treatment of acute myeloid leukemia; CD70 for the treatment of renal cell cancer; and DLL3 for the treatment of small cell lung cancer. The company was founded in 2017 and is headquartered in South San Francisco, California.
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for patients with difficult-to-treat diseases in the United States. Its lead product candidate includes IPI-549 an orally administered immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma) is in Phase 1 clinical study. The company has a license agreement with Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib, a selective inhibitor of the PI3K delta and gamma isoforms, including DUO study that is in randomized Phase III clinical study for patients with relapsed/refractory chronic lymphocytic leukemia and products containing duvelisib; Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; and Takeda Pharmaceutical Company Limited to develop and commercialize duvelisib. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
![](/free-report.png)
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.